Our previous works showed that Ginsenoside Rc can treat NAFLD by activating the SIRT6 protein (Yang et al., 2020); Ginsenoside Rb1 and Ginsenoside Rb3 can alleviate the liver glycolipid model. This evidence concerns the gene SIRT6 and metabolic dysfunction-associated steatotic liver disease.